MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Diffuse large B-cell lymphoma, lymph nodes of multiple sites (C83.38)

HealthDay 26 June at 06.03 PM

Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma

Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress of the European Hematology Association, held from June 13 to 16 in Madrid.Jeremy Abramson, M.D., from the Massachusett

HealthDay 20 June at 04.00 PM

ViPOR Results in Durable Remission in Specific Subtypes of Lymphoma

For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) yields durable remission, according to a study published in the June 20 issue of the New England Journal of Medicine.Christopher Melani, M.D., fro

Evalytics 25 March at 05.57 AM

Some lymphomas become resistant to treatment. Gene discovery may offer path to overcome it.

University of Wisconsin–Madison researchers have uncovered a critical process driving resistance in certain types of lymphoma, offering hope for patients who become resistant to standard treatments. The study focused on understanding why some patients with B-cell malignancies, such as mantle cell lymphoma and diffuse large B-cell lymphoma, develop resistance to Bruton tyrosine kinase inhibitors (B

HealthDay 04 December at 11.21 PM

CAR-T Therapies Not Cost-Effective for Diffuse Large B-Cell Lymphoma

For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a study published online Dec. 5 in the Annals of Internal Medicine.Amar H. Kelkar, M.D., M.P.H., from the Dana-Farbe